Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
(Date:9/30/2014)... , Sept. 30, 2014 In 2011, approximately ... abused prescription pain relievers (e.g. opioids). 1 ... maintenance treatment, which entails the use of buprenorphine, buprenorphine/naloxone, ... treatments are important when developing and improving care management ... benefit manager Prime Therapeutics LLC (Prime). ...
(Date:9/30/2014)... , Sept. 30, 2014  Life Science Angels ... on supporting promising emerging biotech, medical device, genomics, ... the Top Angel Investment Group in the U.S.  ... best performer out of 370 angel groups analyzed ... network strength (connections), selection aptitude and brand recognition.  ...
Breaking Medicine Technology:Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3
... Thousands of jobs in Ohio supported by the biopharmaceutical ... such as imposing new taxes in the Medicare prescription ... From research to technical work, manufacturing to construction ... services, the biopharmaceutical sector supports a broad array of ...
... 27, 2011 Codexis, Inc. (Nasdaq: CDXS ... of a joint development agreement to develop an improved ... is Brazil,s largest sugar and ethanol producer.   ... Codexis will deploy the Codexis CodeEvolver™ directed evolution technology ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:9/30/2014)... Pittsburgh School of Dental Medicine have been awarded a ... Dental and Craniofacial Research, part of the National Institutes ... roots of cleft lip and cleft palate and to ... the Philippines and Pennsylvania. , Orofacial clefts (OFCs), ... that can form when a baby,s mouth doesn,t develop ...
(Date:9/30/2014)... that some stickleback fish fathers can have long-term effects ... fish dads cause their offspring to behave in a ... behavioral changes are accompanied by changes in gene expression, ... in the Proceedings of the Royal Society B: ... that moms are very important for their offspring," said ...
(Date:9/30/2014)... RISC Networks Corporation, the leader ... data center, cloud and core network infrastructure. RISC ... of helping more than 5,000 businesses solve complex ... as IT infrastructure transformation, cloud IaaS and data ... engagement rates and partner growth seen in 2014 ...
(Date:9/30/2014)... 30, 2014 Speaking on this occasion, ... observed ‘Nursing Conference’ as a remarkable event, which brings ... medical and clinical research and diagnostic companies, leading universities ... a perfect platform to share experience, foster collaborations across ... world. Nursing Conference is a forum to explore issues ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
Breaking Medicine News(10 mins):Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3
... Dec. 7 Transcept Pharmaceuticals,Inc. today announced that Glenn ... an expert panel on "Drug Development in a,Changed Environment" ... Westin New York Hotel at Times Square on Thursday, ... multi-company panel will be moderated by Ken Trbovich, Vice,President, ...
... Ventures, a health and life,sciences focused venture capital firm ... of the firm., "We are pleased to name ... Partner of Radius. "David has demonstrated an outstanding,ability to ... have his,energy and continued contribution as we develop Radius ...
... one of the commonest surgical procedures performed on ... both physical and psychological harm, while recent evidence ... debate the issue in this weeks BMJ. , ... infant circumcision, yet ritual (non-therapeutic) male circumcision continues ...
... inadequate and should be replaced with charters of health ... But even these raise ethical tensions, says Harald Schmidt, ... Medical Association (BMA) recently called for a charter setting ... Service and what patients can expect from the NHS. ...
... 7 Bond,Laboratories, Inc. (OTC Bulletin Board: BNDB), a ... file with the NASD to implement,a 2-for-1 forward split ... as of the record date will receive,two (2) shares ... For,example, shareholders owning 5,000 shares prior to the stock ...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 7, ... in,the development of microRNA-based diagnostics and therapeutics, announced,today that ... Rosetta Genomics,will present at RBC Capital Markets 2007 Healthcare ... the Westin Hotel in New York., A live ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference 2Health News:Is infant male circumcision an abuse of the rights of the child? 2Health News:Concept of patients' charters 'inadequate' 2Health News:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: